Compare HP Inc (HPQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? HP Inc trades at $28.79 (market cap $26.59B), while Vertex Pharmaceuticals Incorporated trades at $528.85 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× HP Inc's market cap, and HP Inc pays a 4.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HPQ | VRTX | |
|---|---|---|
Market Cap | $26.59B | $134.25B |
Sector | Technology | Health |
52-Week High | $30.05 | $529.65 |
52-Week Low | $18.20 | $376.62 |
Enterprise Value | $33.75B | $128.37B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $28.72, down 3.62% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $55.3B in 2025, though net margins compressed to 4.45%. The stock offers a dividend yield near 4% and trades at attractive valuations with a P/E of 10.77 and P/S of 0.48. Recent news highlights AI-driven cost savings and a potential 2027 upgrade cycle, while institutional activity shows mixed positioning adjustments.
Outlook: HPQ presents value with low multiples and dividend income, but faces PC market volatility and margin pressure. Risks include competitive threats and debt levels, while catalysts include AI product adoption. Analyst consensus is mixed with a hold rating, but technical strength and earnings consistency support cautious optimism for patient investors.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
